All patients included in the analysis faced a high risk of complications, researchers noted. 

Eric Stecker, MD, chair of the American College of Cardiology's Science and Quality Committee, joined us for an exclusive interview. 

The findings provide further support for the use of dapagliflozin as a new treatment option in HFrEF, regardless of race, the authors suggest. 

This latest analysis tracked more than 300 patients for a median follow-up period of nearly five years.

Outcomes from patients prescribed apixaban, rivaroxaban or dabigatran were compared with outcomes from patients given warfarin. 

Patients taking SGLT2 inhibitors were 22% less likely to die from heart-related causes.